Head to head
Regencell Bioscience vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: RGC · TAK
RGC
Regencell Bioscience
7.11-3.27%
1-year price shape — -65% over the period
Quant Rating E · 2/100
vs
TAK
Takeda Pharmaceutical
18.37+1.49%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (70); Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield.
| RGC | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | -- | -- |
| Last price | 7.11 | 18.37 |
| Change today | -3.27% | +1.49% |
| 1-year return | -64.5% | +29.2% |
| Market cap | $3.53B | $58.68B |
| 52-week range | 4.51 – 69.00 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -296.25 | -55.67 |
| P/E percentile, own 5-yr range | 23rd | 4th |
| P/B | 263.33 | 1.23 |
| Dividend yield | 0.00% | 3.26% |
| Profitability & growth | ||
| EPS (TTM) | -0.02 | -0.31 |
| Net profit (TTM) | $-11.90M | $-977.54M |
| Revenue (TTM) | $3.16B | $4.62T |
| Revenue growth (YoY) | +6.0% | +10.2% |
| Gross margin | 62.3% | 65.5% |
| Operating margin | 8.6% | 10.4% |
| Net margin | 3.6% | -3.5% |
| Free cash flow (TTM) | $159.50M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 0.3% | 51.5% |
| Insider activity (12mo) | 0 buy / 2 sell | 22 buy / 28 sell |
| Short interest (% of float) | 0.2% | 0.1% |
| Analyst consensus | -- | 100% buy (1) |
| Analyst price target | -- | $43 (+134%) |
| StockVane view | ||
| StockVane Quant Rating | E (2) | C (70) |
| Company | ||
| Employees | 10 | 47,029 |
| Founded | 2014 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.